BioSpace News Archive

Business

It’s Full Speed Ahead for Ultragenyx, GeneTx on Angelman Syndrome Trial

GeneTx Biotherapeutics and Ultragenyx Pharmaceutical’s jointly prepared treatment for Angelman syndrome have been provided a green single by DSMB recently.

January 6, 2022
·
2 min read
·
Vanessa Doctor, RN
Deals

Quantum ML Company Rahko Right Fit for Fast-Moving Odyssey

The acquisition is expected to bolster Odyssey’s drug development capabilities in immunology and oncology.

January 6, 2022
·
4 min read
·
Alex Keown
Business

Precision Immunology Biotech Rebrands and Scores $200 Million

Formerly Esker Therapeutics, a San Francisco-based biotech company, now named Alumis, closed on a $200 million Series B financing round to help advance its precision immunology medicines.

January 6, 2022
·
2 min read
·
Mark Terry
Deals

Eli Lilly Drops $50 Million+ for Entos’ Tech

Eli Lilly acquired rights to a technology from Entos Pharmaceuticals that boosts the development of nucleic acid therapeutics for the central and peripheral nervous system.

January 6, 2022
·
3 min read
·
Alex Keown
BioMidwest

Research Roundup: Another Hormone that Regulates Blood Sugar and More Research Stories

Researchers are finding new insights every day about diseases like diabetes that are well understood. For example, new science found another way the body regulates blood sugar levels than just insulin. For that and more research news, continue reading.

January 6, 2022
·
5 min read
·
Mark Terry
Drug Development

New IHU Variant On CDC’s Radar But Currently Not a Concern

What the appearance of yet another variant shows is the “unpredictability of the emergence of SARS-CoV-2 variants,” according to the researchers who discovered IHU.

January 6, 2022
·
4 min read
·
Gail Dutton
Business

Four New Collaborations to Move the World of Drug R&D

As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.

January 6, 2022
·
3 min read
·
Alex Keown
Business

Amgen Strikes Nearly $2 Billion Deal for Protein Therapeutics

Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets.

January 6, 2022
·
2 min read
·
Mark Terry
Drug Development

Promising Phase II Results for Hard-to-Treat Liver Disease

The NASH trial achieved the primary endpoint of proton density fat fraction and the secondary endpoint of cT1.

January 6, 2022
·
2 min read
·
Vanessa Doctor, RN
Business

Eikon Boasts Stellar Leadership Lineup and Massive $518 Million Series B

Founded in 2014 and number 3 on BioSpace’s NextGen Bio “Class of 2022” life science startups to watch, Eikon Therapeutics today closed on a Series B financing worth $517.8 million.

January 6, 2022
·
3 min read
·
Mark Terry